Background -Helicobacter pylori infection in Chile remains as a public and private health-care system's challenge, with a prevalence of the infection over 70%. Nowadays, antibiotic treatment of the infection is mandatory to prevent the arising of severe associated diseases but failures in the eradication therapy mainly due to clarithromycin resistance has been observed worldwide and first line eradication therapy seems to be not effective anymore in several geographical areas. Thus, health-care systems are committed to maintain an epidemiological surveillance upon the evolution of the antibiotic resistance of this priority 2 pathogen. Objective -This work reports a 10 years surveillance of the primary antibiotic resistance of H. pylori clinical isolates at the Biobío region-Chile, and the evolution of resistance toward amoxicillin, clarithromycin, levofloxacin, metronidazole, and tetracycline among the species. Methods -H. pylori strains were investigated during the periods 2005-2007 (1435 patients analysed) and 2015-2017 (220 patients analysed) by inoculating a saline homogenate biopsy onto the surface of Columbia agar (Oxoid, Basingstoke, UK) -supplemented with 7% horse red blood cells plus DENT inhibitor (Oxoid, Basingstoke, UK) -following by incubation at 37ºC under 10% CO 2 atmosphere for five days. Antibiotic resistance pattern of the isolates was assessed using the disk diffusion test in Müeller-Hinton agar supplemented with 7% horse red blood cells followed by incubation for further three days under 10% CO 2 atmosphere. Statistical analysis was done using the SPSS v22 software and P values <0.05 were considered statistically significant. Results -A total of 41% of 1435 patients were detected to be infected with H. pylori by bacteriological culture in 2005-2007 period, meanwhile 32.7% from 220 patients were also infected in 2015-2017 period. The clinical isolates of H. pylori are mostly susceptible to amoxicillin and tetracycline (both over 98% of strains), but less susceptible to levofloxacin in both periods analysed (over 79% of the strains). On the other hand, metronidazole continuous showing the highest score of resistant isolates (over 40% of resistant strains), although an 18% fewer resistant strains were observed in 2015-2017 period. Clarithromycin, the key antibiotic in eradication therapies, has an increased frequency of resistant strain isolated in the decade (22.5% in 2005-2007 and 29.2% in 2015-2017). Multidrug resistant strains (two, three and four antibiotics) were also detected in both periods with the highest scores for simultaneous resistance to clarithromycin-metronidazole (18%) and clarithromycin-metronidazole-levofloxacin (12.5%) resistant strains. According to gender, the isolates resistant to amoxicillin, clarithromycin and metronidazole were more frequent in female, with a specific increment in amoxicillin and clarithromycin resistance. Conclusion -The frequency of clarithromycin resistance (29.2%) detected in 2015-2017 suggests that conventional triple therapy is no longer effective in this region. HEADINGS -Helicobacter pylori, drug effects. Helicobacter infections. Anti-bacterial agents. Bacterial drug resistance. Clarithromycin. Men. Women. Chile.
INTRODUCTION
Chronic Helicobacter pylori infection is causally related to benign and serious malignant upper gastrointestinal diseases, including peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Conversely, eradication of H. pylori is associated with ulcer healing, regression of mucosa-associated lymphoid tissue lymphoma, and decreased cancer risk (1) . Chile has one of the highest rates of H. pylori infection in the world (2, 3) and different studies have shown a prevalence of infection ranging from 60% to 79%, according to socio-economic, educational and health conditions of the population studied (4) . In addition, Merino et al. (5) suggested that in Chile exists an increased risk of infection by H. pylori during the first year of life (up to 23.9 %). Moreover, gastric adenocarcinoma and the high prevalence of H. pylori at younger ages are a major cause of cancer-related mortality (2) .
Antibiotic resistance surveillance of Helicobacter pylori at the Biobío region (Chile) in a decade
Successful treatment for H. pylori infection requires multidrug regimens, which are frequently based on clarithromycin as the central component, and the first-line therapy for eradicating this pathogen includes a widespread regime, which involves the administration of a combination of a proton pump inhibitor (PPI) plus clarithromycin and metronidazole or amoxicillin (6) . However, eradication rates vary with the level of antibiotic resistance prevalence in a particular geographical area and the use of clarithromycin without previous susceptibility testing is not recommended in populations with more than 15%-20% prevalence of resistant isolates (1) . In addition, the Maastricht V Consensus recommended that susceptibility tests should be performed too in these areas at least after a treatment failure (7, 8) .
Special attention is conceited by clarithromycin-resistant isolates of H. pylori -recognized by the World Health Organisation as a high priority species (priority 2) in clinical issues -for which new antibiotics are needed (9) . In Chile, Serrano et al. (10) pointed out the high prevalence of mutation A2143G in clinical isolates from paediatric patients as the main responsible of H. pylori clarithromycin resistance and that it is concomitantly associated to failure in eradicating this infection. On the other hand, the last Florence Consensus Report (Maastricht V) also established that all individuals which have gastritis produced by H. pylori should be treated to avoid progression of associated diseases (7) . Hence, the antibiotic resistance prevalence of H. pylori in geographical areas with high rate of infection and the antibiotic treatment scheme to be used are critical for the successful eradication therapy. Moreover, antibiotic resistance surveillance is also mandatory, especially for detecting clarithromycin resistance among clinical isolates. In this work we inform a 10 years evolution of the antibiotic primary resistance to amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin among clinical isolates of H. pylori at the Biobío-Chile geographic region.
METHODS

Patients and inclusion criteria
Gastric biopsies from 1655 patients submitted to upper gastric endoscopy (UGE) procedure in two periods -first period 2005-2007 (1435 individuals) and second period 2015-2017 (220 individuals) -were analysed for isolating H. pylori. The inclusion criteria were patients that did not receive previously an H. pylori eradication therapy and did not consume antibiotics or proton pump inhibitor in the previous month before the UGE procedure. For the antibiotic resistance study, only those patients whose biopsies were positive for H. pylori bacteriological culture were finally considered in the analyses.
Isolation and identification of H. pylori
Gastric biopsies samples (ca. 2 mm diameter) were processed at the laboratory of Bacterial Pathogenicity, University of Concepcion-Chile. Briefly, each biopsy was grounded in 0.5 mL of saline solution and spread onto the surface of Columbia agar (Oxoid, Basingstoke, UK) supplemented with 7% horse red blood cells plus DENT inhibitor (Oxoid, Basingstoke, UK). Cultures were incubated at 37ºC during 72 h under microaerophilic conditions (10% CO 2 ; Campygen -Oxoid, Basingstoke, UK). Negative cultures were further incubated for seven additional days prior to be considered negative for H. pylori presence. Bacterial identification was done by Gram stain followed by urease, catalase and oxidase tests (11) .
Antibiotics
Amoxicillin, clarithromycin, levofloxacin, metronidazole and tetracycline were investigated. All antibiotics were obtained from Oxoid (Basingstoke, UK). The total number of clinical isolates assayed per antibiotic during the period 2005-2007 were 299 strains for amoxicillin, 333 strains for clarithromycin, 321 strains for levofloxacin, 364 strains for metronidazole, and 311 strains for tetracycline. In the second period, years 2015-2017, a total of 72 clinical isolates were assayed per antibiotic.
Susceptibility test
The disk diffusion test was done according to Lang and García (12) . Antibiotics disk concentration used and their breakpoint criteria for resistance per each antibiotic were as follow: amoxicillin (10 µg disk), diameter of inhibition zone ≤25 mm; clarithromycin (15 µg disk), diameter of inhibition zone ≤21 mm; tetracycline (30 µg disk), diameter of inhibition zone ≤25 mm. The breakpoint criteria for metronidazole (5 µg disk) was: resistant, diameter of inhibition zone <16 mm; intermediate, diameter of inhibition zone 16-21 mm, and susceptible, diameter of inhibition zone >21 mm (13, 14) .
Because no criteria was established for levofloxacin in disk diffusion test upon H. pylori until 2011, in the first period of analysis the criteria proposed for Gram-negative bacteria was used (15) , with 5 µg disk potency. The breakpoint criterium for resistance was, diameter of inhibition zone ≤12 mm (16) .
Statistical analysis
The analyses of the data base were done using SPSS v22 software. The categorical variables were represented by the frequency and percentage of each one of their classes. The chi square test was used to determine differences in percentages and the Mann-Whitney U test was used to compare numerical variables. Level of significance used was 0.05.
RESULTS
Five hundred and seventy-five patients (40.1%) were positive for H. pylori infection in period 2005-2007, as determined by bacteriological culture, and 72 patients (32.7%) were positive in period 2015-2017 (TABLE 1) . This decrease of infected patients in the second period of analysis was mostly due to a lower infection fraction of the female group (56.7% to 52.8%), meanwhile the infected men fraction increased during the 10 years period considered in the analysis (43.3% to 47.2%). The age average of infection in the two periods (TABLE 1) was similar, and the minor differences (47 and 50.6 years old) were not statistically significant (P=0.063). On the other hand, analyses by age among each gender (TABLE  2) showed that female infection has a peak in the 41-50 years old group (45.2%) in 2005-2007, while men showed the peak in the group of 51-60 years old in the same period (46.9%). In contrast, during period 2015-2017 male group showed the highest score of infected individuals between age 21 and 40 years old (TABLE 2) Amoxicillin resistant strains isolated in both periods were of low frequency (2% and 4.2%, respectively) (TABLE 3) . A similar behaviour with tetracycline resistance was observed, because only 1% and 1.4% of the strains showed to be resistant, respectively. On the other hand, a mild increase (6.7%) in the frequency of clarithromycin resistant strains was observed, with frequencies of 22.5% and 29.2% per period, respectively. Regarding levofloxacin, an increase (5.5%) of resistant strains isolated was detected, with a frequency of 15.3 and 20.8% per period. Unexpectedly, a significant decrease (18%, P=0.005) in the frequency for metronidazole resistant strains isolated (55.5% to 37.5%) was observed too.
The frequency of isolation of H. pylori resistant strains among genders also varied in both periods. Thus, among female an increase of 1.8% of amoxicillin resistant strains and 5.3% of clarithromycin resistant strains were observed meanwhile a decrease of 6.6% in the frequency of metronidazole resistant strains isolated was detected too. Levofloxacin resistant strains also showed a mild decrease in female (0.9%). On the other hand, among male both amoxicillin and clarithromycin resistant strains did not vary significantly their frequency of isolation during the two periods analysed. However, a significant increase of 6.4% of levofloxacin resistant strains isolated (P=0.020) and a significant decrease (P=0.019) of metronidazole resistant strains (11.4%) were observed among male group in 2015-2017 period. Tetracycline resistant strains did not vary their frequency of isolation in the two periods studied, independently of the gender (TABLE 5) . (TABLE 4) , with increased prevalence of clarithromycin-metronidazole resistance (5.8%), levofloxacin-metronidazole (5.5%) and clarithromycinlevofloxacin (9.2%) for the 2015-2017 period. Moreover, in this period three and four antibiotic resistant strains were also isolated, with the highest frequency of isolation for the phenotype clarithromycin-levofloxacin-metronidazole resistance (2.2%). Also, resistance frequency of 18% for clarithromycin-metronidazole and 12.5% for both levofloxacin-metronidazole resistance and clarithromycin-levofloxacin were detected too. In addition, isolates resistant to three and four antibiotics were also detected, with the highest score for clarithromycin-levofloxacin-metronidazole isolates (12.5%). 
DISCUSSION
The results show that clinical isolates of H. pylori remain susceptible to amoxicillin, with mild increase in the frequency of isolation of amoxicillin resistant H. pylori strains from 0% among 91 clinical isolates observed during 1999-2000 (17) (18) and Ott et al. (19) , because when a resistance to macrolide appears for any specific pathogen in a particular geographic area, this resistance is rapidly spread and cross resistance to all macrolides is observed too. In addition, Alba et al. (8) pointed out that patients with a history of macrolide consumption are more likely to be carriers of clarithromycin resistant strains. In addition, increasing of clarithromycin resistance could be expected due to its use in the treatment of extra-digestive infections (19) . Recently, Gonzalez-Hormazabal et al. (20) estimated a 31.8% prevalence of clarithromycin resistance in H. pylori at Santiago-Chile by real-time PCR directly from gastric mucosa. These results are higher than the results presented in this work, but it is known that bacteriological cultures underestimate the prevalence of H. pylori as compared to other methods, especially as compared to PCR detection for clarithromycin. Also, Serrano et al. (10) found infected paediatric patients at Santiago-Chile, with high prevalence of the A2143G mutation, responsible for clarithromycin resistance which is indicative of an increased prevalence of this resistance among H. pylori early in childhood. Regarding metronidazole resistance, a frequency of 41.8% was observed among 91 clinical strains in 1999-2000 (17) , which increased to 55.5% in the 2005-2007, but this frequency decreased to 37.5% during in period 2015-2017. This lower frequency of metronidazole resistant has been observed by others, too (21) . The result obtained in 2015-2017 is similar to the frequency of metronidazole resistant strains informed previously by using agar dilution assay (22) . Thus, the differences in percentage of resistant strains isolated observed with metronidazole could be consequence of the method used in the assay (23) . Although disk diffusion test is not the gold standard method for determining H. pylori we used it, since minor variations in detecting primary resistance to clarithromycin has been observed (1, 23, 24) . In addition, the recommended agar dilution test -included it modified version (25) -or the more flexible E-test (26) assays are both time consuming or more expensive than the disk diffusion method to be used for routinely large-scale patient cohorts' analyses, especially in low resources laboratories (27) .
With respect to levofloxacin resistance, an increase of 5.5% in the frequency of isolation in period 2015-2017 was detected. However, the resistance frequency (20.8%) is similar to that informed in a previous work in Argentina (23) . Thus, this antibiotic could be used in triple therapies among adult Chilean patients in areas of increased eradication failures with more conventional therapies as suggested by Fallone et al. (28) , in spite of the adverse effect known to be present in long-term treatment (29) . Moreover, this substitution in the triple therapy should also be considered in geographical areas where the resistance to clarithromycin is over 20% of the clinical isolates and MET resistance frequency among clinical isolates is higher too. In those cases the recommended rescue quadruple therapy (7) will also fail.
Our results showed the arise of simultaneous antibiotic resistant strains among clinical isolates of H. pylori, with increasing prevalence of resistance to clarithromycin-levofloxacin and clarithromycin-levofloxacin-metronidazole. A similar study done in Valdivia (Chile) by Ott et al. (19) reported only five strains of H. pylori with resistance to clarithromycin-metronidazole and only one strain showing simultaneous resistance to three antibiotics (amoxicillin-clarithromycin-metronidazole). On the other hand, Pereira et al. (23) informed two clinical isolates with resistance to metronidazole-clarithromycin and three to metronidazoleclarithromycin-ciprofloxacin simultaneously. The increased frequency in the isolation of multiple resistant strains including amoxicillin-clarithromycin-metronidazole resistance could be the result of the frequent use of these antibiotics in the therapy of gastric H. pylori infection in Chile (19) .
When gender was considered in the analyses, we found the existence of a relationship between the increment in the frequency of isolation of amoxicillin, clarithromycin and levofloxacin resistant H. pylori and female condition in 2015-2017, concomitant with a decrease of metronidazole resistant strains. On the other hand, male showed only a decrease of the metronidazole resistant isolates. Lang and García (12) found that differences in the clinical prevalence of antibiotic resistant strains between gender at Costa Rica were not significant. Although, the authors suggested, that the difference in the level of frequency of metronidazole resistant strains isolated could be a consequence of the use of this antibiotic in gynaecological treatments. Also, the massive use of this antimicrobial agent for the treatment of other infections, such as gynaecologic, dental, gastrointestinal, giardiasis, and amoebiasis could be responsible for the development of metronidazole resistant strains among H. pylori isolated from females (19) . Besides, Lang and García (12) also mentioned the existence of regional differences in the frequency of metronidazole resistance among female in Latin-America. In addition, the worldwide use of antibiotics increased 15% in the last 15 years, being quinolones and macrolides the most consumed (30) , exerting pressure on H. pylori favouring the emergence of resistant strains. This can, in part, explain the increase of amoxicillin, clarithromycin and metronidazole resistant strains in women because they are consuming more antibiotics (31, 32) , therefore the likelihood of selecting resistant strains. The results obtained in this work showed that the epidemiological patterns of the infection caused by H. pylori have changed within the last 10 years. Presently, the infection in men has increased when compared to the previous monitoring and that the associated diagnoses are mainly gastritis and intestinal metaplasia. Despite males continue to be the mostly affected gender; women are the group showing higher rates of resistance to antibiotics, which could be partly explained by the larger intake of them. On the other hand, to continue the regional eradication strategy, the search for alternatives to the use of clarithromycin and metronidazole is recommended because, even though the resistance to the latter is decreasing, it continues to be worryingly high. Finally, it is clear that the triple therapy in Chile, as in many other countries of the world, has become obsolete and it is being not advised in all recent revisions of the consensus, as indicated by Molina-Infante et al. (33) .
CONCLUSION
The frequency of clarithromycin resistant strains in clinical practice detected in 2015-2017 (29.2%) suggests that conventional triple therapy is no longer effective in the Biobío-Chile region.
In addition, keeping in mind the increased resistance observed among the clinical isolates toward antibiotics most commonly used in eradication therapies in the decade, including simultaneous resistance to three and four antibiotics, we call the attention to maintain an epidemiological surveillance upon the evolution of the resistance of this highly prevent pathogen. The searching for new therapeutic alternatives and prophylactic strategies -i.e. probiotic foods, new active molecules against H. pylori from natural origin or the expected vaccine -are mandatory, too.
The use of levofloxacin in the triple therapy should also be considered in geographical areas, like Chile, where the resistance to clarithromycin and metronidazole is high, with increased failure of conventional eradication therapies.
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